To Investigate the Mechanism of Qinpi Tongfeng Formula in Treating Acute Gouty Arthritis by UHPLC-Q-Orbitrap-MS, Network Pharmacology and Experimental Validation
DOI: https://doi.org/10.2147/jir.s454098
IF: 4.5
2024-05-29
Journal of Inflammation Research
Abstract:Yihua Fan, 1– 3, &ast Wei Liu, 1, 2, &ast Yue Jin, 1, 2, &ast Hang Lu, 1, 2 Chunliu Liu, 1, 2 Aihua Wang, 1, 2 Qingxiang Gu, 1, 2 Yuxiu Ka 1, 2 1 Department of Rheumatism and Immunity, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, People's Republic of China; 2 National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, People's Republic of China; 3 Department of Rheumatism and Immunity, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wei Liu, Email Background: Acute gouty arthritis (AGA) is characterized by the accumulation of monosodium urate crystals within the joints, leading to inflammation and severe pain. Western medicine treatments have limitations in addressing this condition. Previous studies have shown the efficacy of Qinpi Tongfeng formula (QPTFF) in treating AGA, but further investigation is needed to understand its mechanism of action. Methods: We used ultra-high-performance liquid chromatography tandem Q-Exactive Orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap-MS) to identify compounds in QPTFF. Target proteins regulated by these compounds were obtained from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, Chemistry Database, and Swiss Target Prediction Database. AGA-related targets were searched and screened from various databases, including Genecards, PharmGKB, Drugbank, etc. Intersection targets of QPTFF and AGA were analyzed for protein–protein interaction networks, GO function enrichment, and KEGG pathway enrichment. We then verified QPTFF's mechanism of action using an AGA rat model, assessing pathological changes via H&E staining and target expression via ELISA, RT-qPCR, and Western blot. Results: UHPLC-Q-Orbitrap-MS identified 207 compounds in QPTFF, with 55 selected through network pharmacology. Of 589 compound-regulated targets and 1204 AGA-related targets, 183 potential targets were implicated in QPTFF's treatment of AGA. Main target proteins included IL-1β, NFKBIA, IL-6, TNF, CXCL8, and MMP9, with the IL-17 signaling pathway primarily regulated by QPTFF. Experimental results showed that medium and high doses of QPTFF significantly reduced serum inflammatory factors and MMP-9 expression, and inhibited IL-17A, IL-6, IKK-β, and NF-κB p65 mRNA and protein expression in AGA rats compared to the model group. Conclusion: Key targets of QPTFF include IL-1β, NFKBIA, IL-6, TNF-α, CXCL8, and MMP9. QPTFF effectively alleviates joint inflammation in AGA rats, with high doses demonstrating no liver or kidney toxicity. Its anti-inflammatory mechanism in treating AGA involves the IL-17A/NF-κB p65 signaling pathway. Keywords: acute gouty arthritis, Qinpi Tongfeng formula, network pharmacology, UHPLC-Q-Orbitrap-MS, IL-17 signaling pathway As a metabolic rheumatic disorder, gout arises from the accumulation of urate in the joints, cartilage, and kidneys when serum uric acid increases to a certain extent due to abnormal purine metabolism in the human body. 1 The presence of acute gouty arthritis (AGA) is indicative of gout during its acute phase, which is characterized by sudden and severe joint pain, often recurrent. 2 Recurrent attacks of AGA can cause urate accumulation in joints, and kidney to cause joint destruction and chronic kidney disease and even renal failure, respectively. 3 Because gout is often accompanied by hyperuricemia, long-term hyperuricemia may cause an elevated risk of cardiovascular and cerebrovascular diseases. 4 The global prevalence of gout ranges from 1% to 6.8%. As modern living standards continue to improve, the prevalence of gout is steadily rising and affecting individuals at younger ages, largely attributed to shifts in dietary patterns and lifestyle habits. 5 For the treatment of AGA, the American College of Rheumatology recommends drugs for inflammation and pain symptoms, which mainly include colchicine and non-steroidal anti-inflammatory drugs (NSAIDs). 6 While the administration of colchicine can promptly alleviate the patient's symptoms, varying levels of negative responses such as hepatic, renal, gastrointestinal impairment, and suppression of bone marrow may occur subsequent to treatment, and the disease is prone to rebound after drug withdrawal. 7,8 NSAIDs also have side effects such as gastrointestinal damage, live -Abstract Truncated-
immunology